Detalhe da pesquisa
1.
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma.
Ann Hematol
; 102(2): 385-392, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36645458
2.
Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Br J Haematol
; 199(3): 339-343, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36002151
3.
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
Hematol Oncol
; 40(1): 31-39, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34694649
4.
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
Eur J Haematol
; 104(6): 581-587, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107795
5.
Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 97(10): 1817-1824, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30054707
6.
Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy.
J Thromb Thrombolysis
; 46(2): 174-179, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29737462
7.
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Br J Haematol
; 172(1): 111-21, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26458240
8.
Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
Br J Haematol
; 164(1): 113-23, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24138497
9.
Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels.
Ann Hematol
; 93(7): 1149-57, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24554303
10.
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Cancers (Basel)
; 16(6)2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539561
11.
Log reduction of leukemic cells and minimal residual disease by flow cytometry represent effective predictors of clinical outcome in elderly patients with acute myeloid leukemia.
Cytometry B Clin Cytom
; 102(1): 26-33, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33983682
12.
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy.
Hemasphere
; 6(12): e798, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36398133
13.
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.
Ther Adv Hematol
; 12: 20406207211048361, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34646432
14.
Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
Cytometry B Clin Cytom
; 98(3): 216-225, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697027
15.
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Thromb Haemost
; 101(2): 233-8, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19190804
16.
Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia.
Eur J Haematol
; 82(3): 235-9, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19067738
17.
Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry.
Am J Hematol
; 84(10): 636-40, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19705431
18.
Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Cytometry B Clin Cytom
; 96(3): 195-200, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30549231
19.
Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.
Leuk Lymphoma
; 59(1): 42-48, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28573902
20.
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
Leuk Res
; 31(11): 1487-93, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17320951